GlassScriptPhysician profile
Isaac Corney
NPI 1710932900
$7,085.67
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $809 · 2020: $261 · 2021: $822 · 2022: $773 · 2023: $3,643 · 2024: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,512 · Travel and Lodging: $1,909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,512.14 |
| Travel and Lodging | $1,908.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,824.82 | 2021-2024 | Gallant, Freestyle Libre 3 |
| Novo Nordisk INC | $743.56 | 2019-2024 | Ozempic, Rybelsus, Tresiba |
| Takeda Pharmaceuticals U.S.A., INC. | $404.11 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $308.67 | 2019-2024 | Airsupra |
| Janssen Pharmaceuticals, INC | $303.39 | 2019-2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $254.41 | 2021-2023 | |
| Glaxosmithkline, LLC. | $158.82 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $155.22 | 2021 | |
| Merck Sharp & Dohme LLC | $124.50 | 2019-2023 | Verquvo |
| Orexo US, INC. | $123.05 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $99.29 | 2019-2022 | |
| Abbvie INC. | $63.05 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.08 | 2022 | |
| Sanofi-Aventis U.S. LLC | $58.72 | 2022 | |
| Scilex Pharmaceuticals INC. | $51.13 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $46.01 | 2019-2020 | |
| Alkermes, INC. | $44.26 | 2019-2022 | |
| Lundbeck LLC | $39.97 | 2019-2020 | |
| Lilly USA, LLC | $36.42 | 2022-2023 | Mounjaro |
| Allergan, INC. | $30.63 | 2020 | |
| Dexcom, INC. | $24.22 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.85 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.48 | 2024 | Gvoke Hypopen |
| Renalytix Ai, INC. | $17.85 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Novartis Pharmaceuticals Corporation | $17.36 | 2022 | |
| Pfizer INC. | $15.48 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.36 | 2023 | Quviviq |
| Mdd US Operations, LLC | $12.96 | 2019 | |
| Amarin Pharma, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Corney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.